1-3 of 3
Lynne A. Bui, MD
Close
Sort by
Journal Articles

A Phase I Study of XL019, a Selective JAK2 Inhibitor, in Patients with Primary Myelofibrosis, Post-Polycythemia Vera, or Post-Essential Thrombocythemia Myelofibrosis

Neil P. Shah, MD, PhD, Patrycja Olszynski, Lubomir Sokol, MD, PhD, Srdan Verstovsek, Ronald Hoffman, MD, Alan F. List, MD, Jorge Cortes, MD, Hagop M Kantarjian, D. Gary Gilliland, Douglas O Clary, PhD, Lynne A. Bui, MD, Martha Wadleigh, MD
Journal: Blood
Blood (2008) 112 (11): 98.
https://doi.org/10.1182/blood.V112.11.98.98
Published: 2008
Journal Articles

A Phase I Study of XL019, a Selective JAK2 Inhibitor, in Patients with Polycythemia Vera

Ronald Paquette, MD, Lubomir Sokol, MD, PhD, Neil P. Shah, MD, PhD, Richard T. Silver, MD, Alan F. List, MD, Douglas O. Clary, Lynne A. Bui, MD, Moshe Talpaz, MD
Journal: Blood
Blood (2008) 112 (11): 2810.
https://doi.org/10.1182/blood.V112.11.2810.2810
Published: 2008
Journal Articles

Preliminary Clinical Activity in a Phase I Trial of the BCR-ABL/IGF- 1R/Aurora Kinase Inhibitor XL228 in Patients with Ph + + Leukemias with Either Failure to Multiple TKI Therapies or with T315I Mutation

Jorge Cortes, MD, Ronald Paquette, MD, Moshe Talpaz, Javier Pinilla, MD, PhD, Ekatherine Asatiani, MD, Meir Wetzler, MD, Jeffrey H. Lipton, MD, PhD, Corynn Kasap, BS, Lynne A. Bui, MD, Douglas O. Clary, PhD, Neil Shah, MD, PhD
Journal: Blood
Blood (2008) 112 (11): 3232.
https://doi.org/10.1182/blood.V112.11.3232.3232
Published: 2008